Eosinophilic dermatosis of hematologic malignancy effectively controlled with omalizumab maintenance therapy.
Overview
abstract
Treatment of eosinophilic dermatosis of hematologic malignancy (EDHM) has been challenging with a minimal response to several modalities. Only systemic corticosteroids have consistently proven successful in suppressing the rash; however, the response is often only partial, and symptoms tend to recur as the dosage is tapered. This demonstrates the need for effective maintenance therapy. Herein, we present a case of EDHM that, following a 1 month prednisone taper and brief trial of narrow-band ultraviolet B phototherapy, has remained well-controlled with omalizumab. This suggests that omalizumab may represent an effective therapeutic alternative in EDHM management with low long-term toxicity.
